Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients

This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1‐OH‐midazolam in morbidly obese patients receiving oral and i.v. midazolam before (n = 20) and one year after weight loss surgery (n = 18), thereby providing insight into the influe...

Descripción completa

Detalles Bibliográficos
Autores principales: Brill, MJE, Välitalo, PAJ, Darwich, AS, van Ramshorst, B, van Dongen, HPA, Rostami–Hodjegan, A, Danhof, M, Knibbe, CAJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728292/
https://www.ncbi.nlm.nih.gov/pubmed/26844012
http://dx.doi.org/10.1002/psp4.12048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728292/
https://www.ncbi.nlm.nih.gov/pubmed/26844012
http://dx.doi.org/10.1002/psp4.12048

Ejemplares similares